Moderate-to-severe Atopic Dermatitis

Immunology
7
Pipeline Programs
4
Companies
4
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
1
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
4100%
+ 3 programs with unclassified modality

On Market (1)

Approved therapies currently available

Regeneron
DUPIXENTApproved
dupilumab
Regeneron
Interleukin-4 Receptor alpha Antagonist [EPC]injection2017

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Regeneron
RegeneronTARRYTOWN, NY
3 programs
1
1
dupilumabPhase 4Monoclonal Antibody
DupilumabPhase 3Monoclonal Antibody
dupilumabN/AMonoclonal Antibody
Sanofi
SanofiPARIS, France
1 program
1
dupilumabPhase 4Monoclonal Antibody1 trial
Active Trials
NCT05590585Completed124Est. Nov 2024
Connect Biopharma
Connect BiopharmaSAN DIEGO, CA
2 programs
2
CBP-201Phase 21 trial
CBP-201Phase 21 trial
Active Trials
NCT05017480CompletedEst. Sep 2023
NCT04444752CompletedEst. Sep 2021
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
QLS12010Phase 21 trial
Active Trials
NCT07344051Not Yet RecruitingEst. Sep 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Sanofidupilumab
Qilu PharmaceuticalQLS12010
Connect BiopharmaCBP-201
Connect BiopharmaCBP-201

Clinical Trials (4)

Total enrollment: 124 patients across 4 trials

NCT05590585Sanofidupilumab

Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial

Start: Jan 2023Est. completion: Nov 2024124 patients
Phase 4Completed
NCT07344051Qilu PharmaceuticalQLS12010

A Phase II Study of QLS12010 Capsules in Adults With Moderate to Severe Atopic Dermatitis

Start: Apr 2026Est. completion: Sep 2027
Phase 2Not Yet Recruiting
NCT05017480Connect BiopharmaCBP-201

A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China

Start: Aug 2021Est. completion: Sep 2023
Phase 2Completed
NCT04444752Connect BiopharmaCBP-201

A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis

Start: Jul 2020Est. completion: Sep 2021
Phase 2Completed

Related Jobs in Immunology

Regulatory Affairs Manager(Immunology), Korea

AbbVie
Seoul, Seoul
6h ago

Regional Sales Trainer - Rheumatology (Mid Atlantic/Central)

AbbVie
Remote
7h ago

Product Specialist - Immunology

Johnson & Johnson
Kibbutz Shefayim, Center District, Israel
20h ago

Senior Area Business Specialist, Immunology - Detroit, MI - Johnson & Johnson Innovative Medicine

Johnson & Johnson
Detroit, Michigan, United States
20h ago

Senior Medical Science Liaison, Dermatology - Indianapolis

Johnson & Johnson
Indianapolis, Indiana, United States
20h ago
$137K - $236K/yr

Field Reimbursement Manager - Rheumatology - Seattle, WA (North)

Johnson & Johnson
Seattle, Washington, United States of America
20h ago
$100K - $175K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
Monoclonal Antibody is the dominant modality (100% of programs)
4 companies competing in this space

Related Indications

Rheumatoid Arthritis(475)Psoriasis(206)Ulcerative Colitis(151)Atopic Dermatitis(144)Crohn's Disease(140)Systemic Lupus Erythematosus(85)Arthritis, Rheumatoid(61)Plaque Psoriasis(53)Crohn Disease(49)Ankylosing Spondylitis(33)